Clinical Nutrition for Diabetes Care Market Trends
Increasing prevalence of diabetes is a major growth driver in the clinical nutrition for diabetes market. For instance, according to IDF Diabetes Atlas 2021, around 537 million adults in world are living with diabetes and the number is projected to rise to 643 million by 2030 and 783 million by 2045.
This expanding patient base requires effective strategies to manage blood glucose levels and overall health, driving the demand for clinical nutrition for diabetes care.
Additionally, there increased awareness and education about the importance of nutrition in diabetes management, particularly in developed countries. This rising awareness drives adoption of clinical nutrition products, as patients seek effective dietary solutions to manage their condition.
Furthermore, growing prevalence of diabetes encourages investment in research and development of new and improved clinical nutrition products, thereby contributing to the market growth.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Clinical nutrition for diabetes care industry reached a revenue of USD 2.2 billion in 2023 and is anticipated to witness 4.8% CAGR from 2024 to 2032, primarily driven by the rising prevalence of diabetes and the increased awareness of the importance of nutrition in diabetes management.
The oral nutrition segment accounted for 65.2% of the market share in 2023, as they are more cost-effective than parenteral or enteral nutrition.
North America clinical nutrition for diabetes care industry accounted for USD 922.1 million in revenue in 2023 and may grow at 4.6% CAGR between 2024 – 2032, led by significant investments in diabetes management and related healthcare services.
Abbott Laboratories, Baxter International Inc., Danone Nutricia, Dr Reddy's Laboratories Ltd., Mead Johnson & Company, LLC, Nestlé Health Science S.A., Nutrego, Otsuka Holdings Co., Ltd., Pfizer Inc., Prohance, and Victus, Inc.